Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.87 USD

0.87
490,626

+0.01 (1.72%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.90 +0.03 (2.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Amarin Corporation PLC [AMRN]

Reports for Purchase

Showing records 341 - 353 ( 353 total )

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 341

03/17/2011

Company Report

Pages: 7

Q4:2010 Update; Expect ANCHOR Results in 1-2 Months

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 342

03/07/2011

Company Report

Pages: 10

Expect Meaningful Upside Upon ANCHOR Success; Raising Fair Value to $12 from $9

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 343

01/06/2011

Company Report

Pages: 6

Prices Secondary Offering of up to $100 million; Lowering FV to $9 from $10 on Dilution

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 344

01/05/2011

Industry Report

Pages: 36

2011 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks.

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 75.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 345

12/29/2010

Company Report

Pages: 6

Expect Positive ANCHOR Data in Early Q2:11, Followed By Potential Takeout; Raising Fair Value to $10 from $7

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 346

12/17/2010

Daily Note

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 347

12/10/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 348

11/29/2010

Company Report

Pages: 7

MARINE Trial Better than Expected

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 349

11/26/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 350

11/12/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 351

11/10/2010

Company Report

Pages: 7

MARINE Data Expected in December; New CEO Appointed

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 352

08/10/2010

Company Report

Pages: 7

MARINE Trial Fully Randomized; Expect Data in Q1:11

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 353

07/19/2010

Company Report

Pages: 22

Under the Radar with a Potential Cardiovascular Blockbuster; Initiating Coverage with an OUTPERFORM Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: NASH D

Price: 75.00

Research Provided by a Third Party